WuXi Biologics (Cayman) Inc. Share Price and Company Fundamentals
Last traded: Today at 8:08 AM
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. It has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company has a strategic collaboration with Sinorda Biomedicine Ltd. for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Key Metrics
PE ratio
36.68
PB ratio
3.26
Dividend yield
-
Beta
0.47
Market cap
$168.10B
Enterprise value
$162.37B
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Full time employees | 12552 |
| Website | https://www.wuxibiologics.com |
| Mailing address | No. 108, Meiliang Road Mashan Wuxi 214092 China |
| Phone / Fax | / |
Dividends
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
WuXi Biologics (Cayman) Inc. paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.2269 dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on WuXi Biologics (Cayman) Inc..
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Ge Li Ph.D. | Founder & Chairman | 58 | |
| Dr. Zhisheng Chen Ph.D. | CEO & Executive Director | 52 | |
| Mr. Ming Tu | CFO & Executive VP | 56 | |
| Lihua Yu M.B.A. | COO & Senior VP | ||
| Dr. Xuejun Gu Ph.D. | CTO, Executive VP of Global Biologics Development Department & Executive Director | 54 | |
| Dr. Jijie Gu Ph.D. | Chief Scientific Officer & President of Global Biologics Research | 59 | |
| Ms. Lina Fan Ph.D. | Senior VP & Head of Investor Relations | ||
| He Wang | General Counsel, Chief Compliance Officer, SVP and Head of Legal & Compliance Department | ||
| Ms. Li Xiong | VP & Head of Global Human Resources | ||
| Mr. Jian Dong | CEO of WuXi Vaccines | 61 |
Profitability and management effectiveness
Profit margin
20.92%
Operating margin
27.37%
Return on assets
5.89%
Return on equity
10.51%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of WuXi Biologics (Cayman) Inc. is 168.10B and its enterprise value is 162.37B. The enterprise value to revenue ratio of 2269 is 8.10. The enterprise value to EBITDA ratio of 2269 is 23.86.
The 2269's stocks Beta value is 0.47 making it 53% less volatile compared to HKEX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
WuXi Biologics (Cayman) Inc. (HKEX:2269) Frequently Asked Questions
1. What is WuXi Biologics (Cayman) Inc.'s Stock Symbol?
WuXi Biologics (Cayman) Inc. trades on HKEX under the ticker symbol "2269".
2. What is WuXi Biologics (Cayman) Inc.'s stock price today?
One share of 2269 stock can currently be purchased for approximately $40.72.
3. How can I contact WuXi Biologics (Cayman) Inc.?
WuXi Biologics (Cayman) Inc.'s mailing address is No. 108, Meiliang Road Mashan Wuxi 214092 China. The company can be reached via phone at .
4. What is WuXi Biologics (Cayman) Inc.'s official website?
The official website of WuXi Biologics (Cayman) Inc. is https://www.wuxibiologics.com.